CD73 overexpression
|
Melanoma
|
CD73 overexpression
|
Melanoma
|
pembrolizumab Resistant: C3 – Early Trials
|
pembrolizumab Resistant: C3 – Early Trials
|
CD73 overexpression
|
Melanoma
|
CD73 overexpression
|
Melanoma
|
nivolumab Resistant: C3 – Early Trials
|
nivolumab Resistant: C3 – Early Trials
|
CD73 overexpression
|
CRC
|
CD73 overexpression
|
CRC
|
cetuximab Sensitive: C3 – Early Trials
|
cetuximab Sensitive: C3 – Early Trials
|
CD73 overexpression
|
Gastric Cancer
|
CD73 overexpression
|
Gastric Cancer
|
pembrolizumab Resistant: C3 – Early Trials
|
pembrolizumab Resistant: C3 – Early Trials
|